All In Biotech

Drug Trial Radar · NCT07675629

Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults

Phase 2a Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A, B, C, A/E) / Gag (C) DNA and gp120 (A, B, C, A/E) Protein HIV-1 Vaccines (PDPHV) With Either Alhydrogel or GLA-SE in Healthy Adults Living Without HIV

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

Aug 31, 2028

Study completion Aug 2029

Sponsor

Lead sponsor
Worcester HIV VaccineIndustry
Sponsor type
Industry
Collaborators
Desmond Tutu Health Foundation; Brigham and Women's Hospital
First posted
Jun 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in healthy, HIV-uninfected adults. Volunteers will receive either the PDPHV or the placebo (normal saline) by intramuscular injections. Some volunteers will receive Alhydrogel and others will receive GLA-SE as part of the protein boost.

Conditions

  • HIV Prevention

Interventions

  • PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))Biological

    The polyvalent DNA Vaccines contains equal amounts of 5 individual DNA plasmid components utilizing the same vector pSW3891. Four plasmids each containing a codon optimized gp120 gene sequence from HIV-1 subtype A, B, C and CRF01\_AE consensus, and a fifth plasmid containing a codon optimized gag gene from subtype C.

  • PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))Biological

    The Recombinant Protein Vaccines (gp120 (A, B, C, A/E)) contains equal amounts of 4 gp120 proteins.

  • Alhydrogel adjuvantBiological

    PDPHV protein vaccines adjuvant

  • GLA-SE adjuvantBiological

    PDPHV protein vaccines adjuvant

  • Placebo for DNA Vaccines, Protein Vaccines and AdjuvantsBiological

    Sodium Chloride for Injection, USP 0.9%.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of local injection site (including DTH) reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  2. Frequency of systemic reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  3. Frequency of adverse events (AEs)Time frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  4. Severity of local injection site (including DTH) reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  5. Severity of systemic reactogenicity signs and symptomsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  6. Severity of adverse events (AEs)Time frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  7. Number of participants with early discontinuation of vaccinationsTime frame: Measured through participants' last study visit, at Month 15 or 18, depending on which part of the study participants are enrolled in
  8. Magnitude of serum HIV-1 Env-specific IgG responsesTime frame: Measured at 2 weeks after the last vaccination at month 6.5
  9. Breadth of gp70-V1V2 IgG and gp120 IgATime frame: Measured at 2 weeks after the last vaccination at month 6.5
  10. ADCC activitiesTime frame: Measured at 2 weeks after the last vaccination at month 6.5

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Emavundleni Clinical Research Site, Desmond Tutu Health Foundation

    Cape Town, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.